DK0951292T3 - Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde - Google Patents
Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfældeInfo
- Publication number
- DK0951292T3 DK0951292T3 DK97944453T DK97944453T DK0951292T3 DK 0951292 T3 DK0951292 T3 DK 0951292T3 DK 97944453 T DK97944453 T DK 97944453T DK 97944453 T DK97944453 T DK 97944453T DK 0951292 T3 DK0951292 T3 DK 0951292T3
- Authority
- DK
- Denmark
- Prior art keywords
- subject
- ischemic disorder
- treating
- sufficient
- comprises administering
- Prior art date
Links
- 230000000302 ischemic effect Effects 0.000 title abstract 7
- 238000000034 method Methods 0.000 abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72144796A | 1996-09-27 | 1996-09-27 | |
| PCT/US1997/017229 WO1998013058A1 (en) | 1996-09-27 | 1997-09-25 | Methods for treating an ischemic disorder and improving stroke outcome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0951292T3 true DK0951292T3 (da) | 2007-08-13 |
Family
ID=24898028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97944453T DK0951292T3 (da) | 1996-09-27 | 1997-09-25 | Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1829550A3 (da) |
| JP (1) | JP2001501612A (da) |
| AT (1) | ATE358492T1 (da) |
| AU (1) | AU4594297A (da) |
| CA (1) | CA2266640C (da) |
| DE (1) | DE69737562T2 (da) |
| DK (1) | DK0951292T3 (da) |
| ES (1) | ES2285740T3 (da) |
| PT (1) | PT951292E (da) |
| WO (1) | WO1998013058A1 (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1712226A3 (en) * | 1996-04-05 | 2007-03-21 | The General Hospital Corporation | Treatment of a Hemoglobinopathy |
| US6315995B1 (en) * | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
| US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
| CA2326634A1 (en) * | 1998-04-01 | 1999-10-07 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
| US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
| FR2816212A1 (fr) * | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire |
| US20030198639A1 (en) * | 2002-04-16 | 2003-10-23 | Frenette Paul S. | Methods of treating sickle cell disease |
| GB0111872D0 (en) * | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
| CN100502650C (zh) * | 2001-06-21 | 2009-06-24 | 贝思·伊斯雷尔·迪科尼斯医药中心 | 一氧化碳改善组织和器官移植结局并抑制细胞凋亡 |
| US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| WO2003066067A2 (en) | 2002-02-04 | 2003-08-14 | Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| SG148850A1 (en) | 2002-02-13 | 2009-01-29 | Beth Israel Hospital | Methods of treating vascular disease |
| PL373002A1 (en) * | 2002-04-15 | 2005-08-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating ileus |
| WO2003088981A1 (en) | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
| CA2482260A1 (en) | 2002-04-15 | 2003-10-30 | Beth Israel Deaconess Medical Center Inc. | Use of heme oxygenase-1 and products of heme degradation |
| US20040052866A1 (en) * | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
| DE10230165A1 (de) | 2002-07-04 | 2004-01-15 | Ino Therapeutics Gmbh | Verfahren und Vorrichtung zur Administration von Kohlenmonoxid |
| CA2504604A1 (en) * | 2002-11-07 | 2004-05-27 | Timothy R. Billiar | Treatment for hemorrhagic shock |
| JP2007526241A (ja) * | 2003-10-22 | 2007-09-13 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞においてスタシスを誘導する方法、組成物、および装置 |
| EP1552840A1 (en) * | 2004-01-07 | 2005-07-13 | Aga Ab | Use of a xenon/carbon monoxide mixture for the protection of cells |
| EP1934236B1 (en) | 2005-09-02 | 2012-11-21 | GlycoMimetics, Inc. | Heterobifunctional pan-selectin inhibitors |
| US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| EP2356224A4 (en) * | 2008-11-10 | 2012-12-26 | Sinai School Medicine | METHOD OF INHIBITING WEB TREATMENT IN CONNECTION WITH INFLAMMATION THROUGH NEUTROPHILACTIVITY INHIBITION |
| CN101732348B (zh) * | 2008-11-11 | 2015-01-14 | 威世药业（如皋）有限公司 | 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途 |
| WO2012037034A1 (en) | 2010-09-14 | 2012-03-22 | Glycomimetics, Inc. | E-selectin antagonists |
| WO2012145520A2 (en) | 2011-04-19 | 2012-10-26 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
| EP2734235B1 (en) | 2011-07-21 | 2017-03-22 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
| HUE036253T2 (hu) | 2011-12-22 | 2018-06-28 | Glycomimetics Inc | E-szelektin antagonista vegyületek |
| US9738884B2 (en) | 2012-04-27 | 2017-08-22 | Nihon University | Therapeutic agent for epithelial and endothelial injury |
| DK2928476T3 (da) | 2012-12-07 | 2018-05-22 | Glycomimetics Inc | Forbindelser, sammensætninger og fremgangsmåder ved anvendelse af e-selectin-antagonister til mobilisering af hæmatopoietiske celler |
| US10519181B2 (en) | 2014-12-03 | 2019-12-31 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
| US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
| JP2019524791A (ja) | 2016-08-08 | 2019-09-05 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ |
| US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
| WO2018169853A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| JP7275131B2 (ja) | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| WO2019133878A1 (en) | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| CN111867601A (zh) | 2018-03-05 | 2020-10-30 | 糖模拟物有限公司 | 用于治疗急性髓系白血病及相关病症的方法 |
| WO2020139962A1 (en) | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378464A (en) * | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
| EP0642577B1 (en) * | 1992-05-22 | 2004-03-10 | Montana State University | Antibodies with specificity for multiple adhesion molecules |
| US5591835A (en) * | 1992-06-29 | 1997-01-07 | Glycomed Incorporated | Substituted lactose derivatives |
| WO1994005314A1 (en) * | 1992-09-08 | 1994-03-17 | Centocor, Inc. | Peptide inhibitors of leukocyte adhesion |
| EP0671951A4 (en) * | 1992-12-01 | 1997-05-21 | Protein Design Labs Inc | HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN. |
| EP0747059A1 (en) * | 1994-01-28 | 1996-12-11 | Japan Tobacco Inc. | Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane |
| DE4403057C1 (de) * | 1994-02-02 | 1994-12-08 | Biotest Pharma Gmbh | Thrombozytenstabilisierende Faktor IX-Fragmente, deren Herstellung sowie sie enthaltende Arzneimittel |
| DE4421433C1 (de) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung |
-
1997
- 1997-09-25 DK DK97944453T patent/DK0951292T3/da active
- 1997-09-25 AU AU45942/97A patent/AU4594297A/en not_active Abandoned
- 1997-09-25 AT AT97944453T patent/ATE358492T1/de active
- 1997-09-25 CA CA2266640A patent/CA2266640C/en not_active Expired - Fee Related
- 1997-09-25 ES ES97944453T patent/ES2285740T3/es not_active Expired - Lifetime
- 1997-09-25 EP EP07006886A patent/EP1829550A3/en not_active Withdrawn
- 1997-09-25 JP JP10515905A patent/JP2001501612A/ja active Pending
- 1997-09-25 EP EP97944453A patent/EP0951292B1/en not_active Expired - Lifetime
- 1997-09-25 WO PCT/US1997/017229 patent/WO1998013058A1/en active IP Right Grant
- 1997-09-25 PT PT97944453T patent/PT951292E/pt unknown
- 1997-09-25 DE DE69737562T patent/DE69737562T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1829550A2 (en) | 2007-09-05 |
| EP1829550A3 (en) | 2008-04-30 |
| EP0951292A4 (en) | 2004-08-04 |
| DE69737562D1 (de) | 2007-05-16 |
| ES2285740T3 (es) | 2007-11-16 |
| EP0951292B1 (en) | 2007-04-04 |
| PT951292E (pt) | 2007-06-18 |
| WO1998013058A1 (en) | 1998-04-02 |
| JP2001501612A (ja) | 2001-02-06 |
| ATE358492T1 (de) | 2007-04-15 |
| CA2266640A1 (en) | 1998-04-02 |
| EP0951292A1 (en) | 1999-10-27 |
| AU4594297A (en) | 1998-04-17 |
| CA2266640C (en) | 2011-05-24 |
| DE69737562T2 (de) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0951292T3 (da) | Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde | |
| DE69722426D1 (de) | Isobutylgaba und dessen derivate zur schmerzbehandlung | |
| ATE481970T1 (de) | Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum | |
| EA200401070A1 (ru) | Способы лечения сосудистых заболеваний | |
| ATE404522T1 (de) | Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung | |
| EA200401365A1 (ru) | Способы лечения илеуса | |
| NO963742L (no) | Fremgangsmåte til å stimulere hematopoese med hemaglobin | |
| DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
| DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
| CY1118924T1 (el) | Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
| ATE291918T1 (de) | Kombinationstherapie zur behandlung von tumoren | |
| DK0799618T3 (da) | Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer | |
| HU9701060D0 (en) | Pharmaceutical composition for treating cognitive disturbs | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| MXPA01007952A (es) | Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas. | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| DE59510674D1 (de) | Verwendung von selegilin zur behandlung von epileptischen erkrankungen | |
| TR199801801T2 (xx) | Madde k�t�ye kullan�m�n�n tedavisi. | |
| HRP20080389A2 (en) | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | |
| DK0836853T3 (da) | Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom | |
| ES2122236T3 (es) | Sal de lisina de la 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida. | |
| DK1019066T3 (da) | Fremgangsmåder og præparater til forebyggelse og behandling af halsbrand |